Global Autoimmune Diseases Diagnostics Market is projected to be valued at around US$ 8.64 Billion by 2030. Autoimmune diseases are diverse situations wherein the immune system mistakenly attacks the body's cells, tissues, and organs. These outcomes result in irritation and harm, causing various symptoms. Over 80 diagnosed autoimmune diseases, together with rheumatoid arthritis, lupus, and type 1 diabetes, affect millions globally. The precise motive is frequently unknown, related to a complex exchange of genetic and environmental elements. Symptoms range widely, impacting more than one system and organ. Diagnosing autoimmune sicknesses may be challenging, regularly requiring specialized testing. Treatment aims to cope with signs and symptoms and modulate the immune response, improving the patient's friendly life.
According to NCBI, approximately 5% of the world’s population suffers from autoimmune disorders, which are lifelong and functionally diverse and are steadily increasing in Westernized societies. Immune reactions that are targeted toward self-antigens can eventually lead to the destruction of the host’s cells and the improvement of autoimmune diseases. Although autoimmune disorders are comparatively rare, the global incidence and prevalence are growing, and they have substantial damaging implications for mortality and morbidity.
Surging cognizance prompts early consultations for autoimmune illnesses, propelling the demand for specialized diagnostics and personalized treatment plans. Leveraging autoantibody assays, genetic testing, imaging, and diagnostics offers particular results. Robots streamline labs, while point-of-care testing complements accessibility. AI accurately predicts sickness dangers, promising a vibrant future for customized treatments. In the United States, the autoimmune disease diagnostics market is projected to develop appreciably because of new product introductions and the presence of primary companies. These elements contribute to the market's dominance and expected increase throughout the forecast period. Hence, the worth of the Global Autoimmune Diseases Diagnostics Market was US$ 5.32 Billion in 2023.
2. Diagnostics Equipment
3. Drugs
2. Localized Autoimmune Disease Diagnostics
2. Diabetes
3. Multiple Sclerosis
4. Inflammatory Bowel Disease
5. Others
2. Diagnostics Centers
3. Others
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Siemens Healthineers
5. Bio Merieux SA
6. Myriad Genetics, Inc.
7. Quest Diagnostics Incorporated
8. Thermo Fisher Scientific Inc.
According to NCBI, approximately 5% of the world’s population suffers from autoimmune disorders, which are lifelong and functionally diverse and are steadily increasing in Westernized societies. Immune reactions that are targeted toward self-antigens can eventually lead to the destruction of the host’s cells and the improvement of autoimmune diseases. Although autoimmune disorders are comparatively rare, the global incidence and prevalence are growing, and they have substantial damaging implications for mortality and morbidity.
Global Autoimmune Diseases Diagnostics Market is projected to experience a CAGR of 7.17% between 2024 and 2030
The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market. This demographic shift opens a new and expanding phase for diagnostics, contributing to a heightened market boom. The market studies a banquet of new biomarkers and tests for rarer autoimmune diseases, catering to numerous patients' needs. The market is increasing with rising healthcare spending, propelled by improved public and private funding globally. Expanded insurance coverage, in addition, complements accessibility to diagnostics, making these tests available to a broader population. This combination creates a flourishing market environment with various services and financial support.Surging cognizance prompts early consultations for autoimmune illnesses, propelling the demand for specialized diagnostics and personalized treatment plans. Leveraging autoantibody assays, genetic testing, imaging, and diagnostics offers particular results. Robots streamline labs, while point-of-care testing complements accessibility. AI accurately predicts sickness dangers, promising a vibrant future for customized treatments. In the United States, the autoimmune disease diagnostics market is projected to develop appreciably because of new product introductions and the presence of primary companies. These elements contribute to the market's dominance and expected increase throughout the forecast period. Hence, the worth of the Global Autoimmune Diseases Diagnostics Market was US$ 5.32 Billion in 2023.
Diagnostics Equipment has a solid claim to the leading position in the global autoimmune diseases diagnostics market
By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs. An accurate and well-timed prognosis is vital in dealing with autoimmune diseases. Diagnostics Equipment, from blood analyzers to imaging systems, identifies situations early, improving effects. With a vast variety of tests, such as specialized imaging, it caters to various needs. Technological advancements, like AI and automation, drive growth. Rising occurrence fuels demand for supporting innovation. Personalized treatment is based on correct analysis. Supportive regulations and insurance coverage enhance accessibility. Streamlined workflows and automation lessen mistakes. Early intervention ability promises disease prevention.Systemic autoimmune diseases (SADs) hold a significant portion of the global autoimmune diseases diagnostics market
The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics. Systemic autoimmune diseases (SADs) impose considerable morbidity and mortality, often necessitating lifelong treatment and monitoring, hence driving demand for specialized diagnostics. Notable improvements, including noticeably precise autoantibody assays, genetic testing for susceptibility markers, and advanced imaging strategies, enhance diagnostics accuracy and efficiency, bolstering market growth. Early detection is pivotal in coping with SADs efficaciously, lowering disease development and organ damage, thereby fostering demand for reachable and precise diagnostics tools. With elevated consciousness of SADs and their effects, individuals are proactively in search of medical interest and screening tests, in addition to stimulating market enlargement.Rheumatic disease diagnostics occupy a substantial share in the autoimmune diseases diagnostics market
By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others. Rheumatic diseases, affecting 1 in 4 adults globally, fuel tremendous demand for diagnostics. Diverse subtypes like rheumatoid arthritis and lupus require precise diagnostics techniques, propelling the improvement of a vast range of tests. Diagnosis complexity, with overlapping signs, mandates advanced strategies like autoantibody assays and genetic testing. Early detection is essential for capable management and decreasing joint damage. Research emphasizes novel diagnostics Equipment, enhancing accuracy and permitting personalized medicine. This shift towards tailor-made remedies underscores the significance of correct diagnostics in predicting disorder development and guiding interventions.Diagnostics centers are expected to hold a significant share in the global autoimmune diseases diagnostics market
By end-users, the global autoimmune diseases diagnostics market is divided into Hospitals, Diagnostics Centers, and Others. Specialized diagnostics centers excel in autoimmune disease, testing with targeted expertise, and providing quicker, correct diagnoses using cutting-edge technology. They prioritize patient satisfaction because they are cost-effective, easily located, and aligned with value-based care. Collaboration with primary care physicians streamlines referrals, ensuring suitable testing is done. Integrated digital structures enhance efficiency. Amidst the surge in outpatient services, diagnostics facilities become pivotal in autoimmune disease diagnosis and control, playing a valuable function in the evolving healthcare panorama.Asia-Pacific is undoubtedly a key player in the global autoimmune diseases diagnostics market, and its potential for continued expansion is significant
By regions, the global autoimmune diseases diagnostics market is broken up into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, and UAE). Asia-Pacific, home to over half the worldwide population, faces a rising burden of autoimmune diseases. According to the Arthritis Foundation of Asia, about 47 percent of diabetes and 49 percent of heart patients are diagnosed with arthritis. The region's adoption of cost-effective diagnostics solutions and growing disposable earnings expand access to diagnostics, propelling market increase. Strategic initiatives, like Avesthagen Limited's alliance with Wipro Limited in June 2022 to commercialize genetic testing in India, similarly make contributions. Partnerships like these are expected to strengthen market expansion in the place.Key Players
The global autoimmune diseases diagnostics market is comprised of companies such as Abbott Laboratories, Bio-Rad Laboratories, Roche Diagnostics, Siemens Healthineers, Bio Merieux SA, Myriad Genetics, Inc., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.- In August 2022 - KSL Beutner Laboratories (Beutner) developed a blood test to detect an antigen associated with mucous membrane pemphigoid (MMP). This autoimmune blistering disease often causes painful lesions in the oral cavity.
- In May 2022 - The Phadia 2500+ instruments by ThermoFisher will soon offer reliable and unparalleled high throughput for allergy diagnostics and autoimmune testing in the US.
Product - Global Autoimmune Diseases Diagnostics Market breakup in 3 viewpoints:
1. Therapeutic & Monitoring Equipment2. Diagnostics Equipment
3. Drugs
Types - Global Autoimmune Diseases Diagnostics Market breakup in 2 viewpoints:
1. Systemic Autoimmune Disease Diagnostics2. Localized Autoimmune Disease Diagnostics
Indication - Global Autoimmune Diseases Diagnostics Market breakup in 5 viewpoints:
1. Rheumatic Disease2. Diabetes
3. Multiple Sclerosis
4. Inflammatory Bowel Disease
5. Others
End-Users - Global Autoimmune Diseases Diagnostics Market breakup in 3 viewpoints:
1. Hospitals2. Diagnostics Centers
3. Others
Countries - Global Autoimmune Diseases Diagnostics Market of 25 Countries
1. North America1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Developments
- Revenue Analysis
Company Analysis:
1. Abbott Laboratories2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Siemens Healthineers
5. Bio Merieux SA
6. Myriad Genetics, Inc.
7. Quest Diagnostics Incorporated
8. Thermo Fisher Scientific Inc.
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary5. Global Autoimmune Disease Diagnostics Market
4. Market Dynamics
6. Market Share - Autoimmune Disease Diagnostics Market
7. Product - Autoimmune Disease Diagnostics Market
8. Type - Autoimmune Disease Diagnostics Market
9. Indication - Autoimmune Disease Diagnostics Market
10. End Users - Autoimmune Disease Diagnostics Market
11. Country - Autoimmune Disease Diagnostics Market
12. Porter’s Five Analysis - Autoimmune Disease Diagnostics Market
13. SWOT Analysis - Autoimmune Disease Diagnostics Market
14. Companies Analysis
List of Figures:
List of Tables:
Companies Mentioned
- Abbott Laboratories
- Bio-Rad Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Bio Merieux SA
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
